Mirai Medical

What Mirai Medical does

Mirai Medical is an Ireland-based medical device company developing ePORE® Therapy, a platform that applies endoscopic pulsed electric fields (ePORE) to ablate gastrointestinal disease tissue. The company's stated vision is to transform the treatment of gastrointestinal diseases by pioneering this modality, delivering what it describes as a safe, fast, and effective ablation solution that can be used by endoscopists during routine endoscopic procedures. The ePORE trademark is registered, and PIONEER technology development was funded by an $8.4 million raise in 2025, supported by Health Innovation Netherlands (HI-NL), positioning PIONEER as the next-generation iteration of the platform.

The target customer is the clinical user: gastroenterologists and endoscopists performing GI ablation procedures. Customer segmentation is described as horizontal (a single persona across the GI endoscopy workflow), and no named hospital systems, distributors, GPOs, or channel partners are disclosed. The company employs standard digital demand-generation tactics (LinkedIn, Google remarketing, Facebook Pixel, monthly opt-in email newsletter) consistent with a pre-commercial company building awareness ahead of a future launch. No pricing model, reimbursement strategy, distributor agreements, or salesforce footprint is disclosed.

Mirai Medical is privately held, headquartered at 5 Howley Court, Oranmore, Galway, Ireland, with 1–10 employees. The company previously participated in the MedTech Innovator program (2023). Only one executive is publicly disclosed (Colin Forde, COO). There is no disclosed FDA clearance, CE mark, clinical trial readout, or commercial revenue; the company's evidence base points to an R&D-stage medtech advancing its platform toward regulatory and commercial milestones in 2026 and beyond.

Name

Mirai Medical

Legal name

Mirai Medical

Website

https://mirai-medical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Mirai Medical is an Ireland-based medical device company developing the ePORE endoscopic pulsed electric field ablation platform for treating gastrointestinal diseases, targeting gastroenterologists and endoscopists as users. The PIONEER next-generation platform is funded by an $8.4 million 2025 raise from Health Innovation Netherlands.

Ownership category

akta.pro rank

Product category

Endoscopic Ablation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industry

Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC)

Keywords

• Endoscopic ablation therapy
• Pulsed electric fields
• Gastrointestinal treatment
• Medical device platform
• Minimally invasive ablation

Headquarters

HQ city

Oranmore

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Regulatory or Compliance

Marketing channels4 records

Core offering

Mirai Medical develops and commercializes the ePORE® Therapy platform, an endoscopic pulsed electric field (ePORE) ablation technology for the treatment of gastrointestinal diseases. The platform enables endoscopists to perform safe, fast, and effective tissue ablation procedures via endoscopy, providing a scalable therapeutic solution for GI disease management. The company's next-generation PIONEER technology development is supported by an $8.4 million funding round.

Product overview

Mirai Medical offers a single unified product platform called ePORE® Therapy, which utilizes pioneering endoscopic pulsed electric fields technology for treating gastrointestinal diseases. The company's scalable platform empowers endoscopists with a safe, fast, and effective ablation solution. The PIONEER technology development (funded by $8.4M in 2025) represents the next generation advancement of this core platform technology.

Differentiator

Problem solved

Functional benefit

Brands

• ePORE® Therapy: Pioneering endoscopic pulsed electric fields technology for the treatment of gastrointestinal diseases. A scalable ablation platform empowering endoscopists with a safe, fast, and effective solution.

Products and services

• ePORE® Therapy An endoscopic pulsed electric fields ablation therapy platform designed for the treatment of gastrointestinal diseases. It enables endoscopists to perform safe, fast, and effective ablation procedures and is positioned as a scalable platform technology.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Pentax Medical (HOYA Group):
• Medtronic: Global medical device leader that acquired Covidien and owns the Barrx franchise — a market-leading endoscopic radiofrequency ablation system for Barrett's esophagus and GI conditions. Comparable as the dominant incumbent in GI endoscopic ablation and a likely strategic acquirer of ePORE-class technologies.
• Cook Medical: Privately held medical device manufacturer with a substantial GI endoscopy franchise (stents, dilation, hemostasis, and ablation accessories). Comparable as a broad incumbent GI accessory supplier with overlapping customer relationships in endoscopy suites.
• Boston Scientific: Major medtech company with a broad GI endoscopy portfolio including hemostasis, resection, and ablation tools sold to gastroenterologists. Comparable as a large incumbent serving the same endoscopist customer base with adjacent ablation and tissue-removal solutions.
• Olympus Corporation: Global leader in flexible endoscopy systems with broad therapeutic accessory portfolio. Comparable as the dominant endoscope and GI accessory supplier whose installed base determines which ablation accessories gain hospital adoption.

Direct peers

• AngioDynamics: US-listed medical device company with NanoKnife, an irreversible electroporation (pulsed electric field) system used for soft tissue ablation. Comparable as a peer using pulsed electric field energy for tissue ablation, validating the modality while representing a potential strategic or competitive threat in endoscopic delivery.
• Creo Medical: UK-based micro-cap medical device company developing endoscopic ablation technologies (Speedboat, MicroBlate) for GI and other endoscopic applications. Directly comparable as a small-cap endoscopic ablation innovator targeting similar gastroenterologist customers with energy-based tissue treatment.
• ERBE Elektromedizin: German specialist in electrosurgical and pulsed-field technology for endoscopy and surgery. Highly comparable as a developer of energy-based therapeutic devices for GI endoscopy, with overlapping electroporation / pulsed electric field IP and a similar specialist customer base.

Emerging players

• Galvanize Therapeutics (formerly CPSI Biotech): Clinical-stage developer of pulsed electric field (Aliya) and pulsed field ablation systems primarily for oncology and cardiac applications. Comparable as an emerging peer commercializing pulsed electric field technology, with potential overlap in endoscopic applications as the platform expands.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mirai-medical/?originalSubdomain=ie
• Xx.com/Mirai_Medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirai Medical